Sagimet Biosciences Inc - Series A —— 季度现金流量表 (NASDAQ:SGMT) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

总资产 160.26 M146.17 M137.41 M128.4 M116.48 M 负债总额 4.45 M7.18 M7.25 M9.15 M5.1 M 权益总额 155.81 M138.99 M130.16 M119.25 M111.38 M 负债及股东权益总额 160.26 M146.17 M137.41 M128.4 M116.48 M 总债务 ————— 净债务 —————

新闻

Citizens重申Sagimet Biosciences股票评级,MASH研发取得进展

Citizens reiterates Sagimet Biosciences stock rating on MASH progress

Oppenheimer重申Sagimet股票评级,看好MASH试验进展

Oppenheimer reiterates Sagimet stock rating on MASH trial progress

Sagimet生物科学股票在痤疮药物安全性数据积极后上涨

Sagimet stock rises after positive Phase 3 safety data for acne drug

Ascletis reports positive long-term safety data for acne drug denifanstat

Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market (SGMT)

Sagimet reports positive Phase 1 results for MASH combination therapy

Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)

歌礼制药-B(01672)：同类首创FASN抑制剂地尼法司他(ASC40)治疗痤疮的新药上市申请获国家药监局受理

Sagimet Biosciences executive chairman sells $290k in shares